U.S. Biotech Stock News

In late March 2026, Allegro MicroSystems was swept up in a sector-wide reaction after Nvidia announced a partnership and US$2.00 billion investment in Marvell Technology, lifting sentiment across semiconductor names. This broad-based move highlighted how Allegro’s share price can be influenced not only by its own fundamentals but also by investor expectations tied to major industry capital commitments and geopolitical supply chain risks. With that backdrop of sector optimism following...

In recent months, CF Industries Holdings reported strong nitrogen fertilizer demand, advanced low-carbon ammonia projects like the Donaldsonville CCS partnership with ExxonMobil, and continued large share repurchases, while an executive sold about US$540,000 of stock near a one-year high. The company’s long-term, very large compounded return over the past two decades highlights how sustained cash generation and reinvestment can materially reshape investor outcomes over time. We’ll now...

Several law firms have launched investigations into PennyMac Financial Services (PFSI) after a significant decline in servicing segment pretax income raised questions about prior disclosures and potential securities law violations. See our latest analysis for PennyMac Financial Services. The share price has recently shown a short burst of strength, with a 1-day share price return of 2.74% and 7-day return of 5.42%. However, this follows a 90-day share price decline of 32.89% and a...

AngloGold Ashanti (AU) has been back in focus after a rebound in gold miners, record free cash flow, a sizable dividend, and new tender offers for its notes, alongside progress at the Arthur Gold Project. See our latest analysis for AngloGold Ashanti. Despite a 2.2% pullback in the latest session, AngloGold Ashanti’s 18.3% year to date share price return and very large 1 year total shareholder return suggest momentum has been building as investors respond to stronger cash generation,...

Wave Life Sciences has reported past interim Phase 1 INLIGHT data showing that a single 240 mg dose of WVE-007 in adults with overweight or obesity produced statistically significant, six‑month reductions in visceral fat and waist circumference, with preserved lean mass and a generally favorable safety profile. An intriguing insight is that WVE-007 delivered greater six‑month improvement in visceral fat‑to‑muscle ratio than weekly semaglutide in a trial enrolling people with higher average...

OceanFirst Financial (OCFC) is drawing attention after a recent 1 day move of 1.1%, adding to a roughly 4.7% gain over the past week and modest gains over the past month. See our latest analysis for OceanFirst Financial. The recent 7 day share price return of 4.7% adds to a 90 day gain of 3.1%, while the 1 year total shareholder return of 26.7% contrasts with a slightly negative 5 year total shareholder return. This suggests momentum has strengthened more recently than over the longer...

Recent analyst updates on PepsiCo (PEP) spotlight rising cost inflation and demand risks linked to Middle East tensions, while upcoming earnings and the company’s health focused product pipeline are drawing fresh attention from investors. See our latest analysis for PepsiCo. PepsiCo’s share price has been firming up recently, with a 1.53% 1 day and 12.21% 90 day share price return, while its 1 year total shareholder return of 11.38% contrasts with a softer 3 year record. If recent moves in...

What Diamondback Energy’s Recent Performance Tells Investors Without a clear news catalyst, Diamondback Energy (FANG) has still drawn attention as the share price closed at $193.88, with recent returns ranging from a 1 day gain to mixed weekly performance. Over the past month the stock shows a 7.39% return, extending to 31.90% over the past 3 months and 27.27% year to date, with a 61.44% total return over the past year. See our latest analysis for Diamondback Energy. The recent move to a...

Liberty Energy (LBRT) has completed a US$475 million zero coupon convertible note offering due 2032, expanding its previously announced deal and bringing Goldman Sachs and J.P. Morgan Securities in as co lead underwriters. See our latest analysis for Liberty Energy. The financing comes as Liberty Energy's share price sits at US$28.10, with a 90 day share price return of 49.15% and a 1 year total shareholder return of 160.29%, indicating that momentum has been strong recently. If this kind of...

In March 2026, Tenable Holdings announced Tenable Hexa AI, an agentic AI engine within the Tenable One Exposure Management Platform that automates security workflows and coordinates machine-speed responses to cyber risk across IT, cloud, identity, OT and AI environments. By using its Exposure Data Fabric to understand how vulnerabilities, identities, assets, configurations and AI systems interact, Tenable Hexa AI aims to prioritize what matters most and orchestrate repeatable, human‑guided...

Short interest surge puts H2O America (HTO) under closer investor scrutiny A 210% jump in short interest in March has pushed H2O America (HTO) into focus, as a growing group of traders is positioning for downside and signaling expectations of elevated share price swings. See our latest analysis for H2O America. At a share price of US$59.18, H2O America has a 1-day share price return of 1.27% and a 90-day share price return of 18.69%. The 1-year total shareholder return of 14.40% contrasts...

Why NNN REIT (NNN) is on income investors’ radar NNN REIT (NNN) continues to attract attention as a long-tenured dividend payer, with 36 consecutive years of annual dividend increases and a portfolio of 3,692 net lease properties across the United States. The stock recently closed at $42.77, with a market value of about $8.1 billion. Recent total returns range from a negative month performance to gains over the past 3 months, year to date, and across the past 1, 3, and 5 years. See our latest...

Peoples Bancorp recently reported three consecutive quarters of improving earnings per share, supported by strong loan portfolio growth and tighter cost control, and previously announced it would release its first quarter 2026 results and hold an earnings call on April 21, 2026. This pattern of loan-driven earnings improvement is giving the bank greater financial flexibility and could influence how investors view its longer-term prospects and risk profile. Next, we’ll examine how this run of...

Atour Lifestyle Holdings (NasdaqGS:ATAT) has been in focus after its latest quarterly report topped earnings expectations, completed the “2,000 Premier Hotels” initiative, and introduced a new three year “Brand Led Excellence” plan. See our latest analysis for Atour Lifestyle Holdings. Atour’s latest earnings beat and new “Brand Led Excellence” plan have arrived after a mixed share price stretch, with a 4.47% 7 day share price return but a 9.08% 90 day decline. At the same time, the 1 year...

In March 2026, Expro Group Holdings’ board approved a plan to move its corporate domicile from the Netherlands to the Cayman Islands, while the company also agreed to provide advanced GeoFlow™ surface well testing and related services to support VERCANA GmbH and Vulcan Energy’s Lionheart geothermal and lithium project in Europe. The planned redomicile highlights management’s focus on governance flexibility and corporate simplification, while the Lionheart engagement underscores Expro’s role...

Saia (SAIA) moved higher in response to broader market relief after reports that President Trump was considering de-escalation of the military conflict in Iran, which eased worries about energy costs and industrial activity. See our latest analysis for Saia. At a latest share price of $354.28, Saia has a 7 day share price return of 5.97% and a 1 year total shareholder return of 9.90%, suggesting recent momentum has picked up after a more measured longer term outcome. If this kind of move has...

CMS coding update puts Inspire Medical Systems (INSP) in focus Recent confirmation that new CMS hypoglossal nerve stimulation C codes will share the same APC 5465 as CPT 64582, keeping hospital facility fees broadly unchanged, has put Inspire Medical Systems (INSP) back on investor watchlists. See our latest analysis for Inspire Medical Systems. The latest CMS coding clarity arrives as the share price trades at US$54.99, with a 1 day share price return of 2.52% and a 7 day share price return...

Analyst optimism and recent stock move Recent upward revisions to earnings estimates and revenue forecasts for Everpure (PSTG), together with a consensus Outperform rating, have coincided with the stock outperforming the broader market in recent trading sessions. See our latest analysis for Everpure. At a share price of US$62.48, Everpure has recently posted a 2.31% 1 day share price return and a 5.93% 7 day share price return. However, its 90 day share price return shows a decline of 10.31%,...

Legend Biotech recently reported record quarterly sales and profitability milestones for its CARVYKTI multiple myeloma therapy, alongside expanded global access and the past removal of FDA REMS restrictions that had limited how patients were monitored and allowed to drive. These updates highlight how CARVYKTI has become one of the most widely used CAR-T treatments, supported by long-term survival data, growing manufacturing capacity and broader international launches that together could...

DXP Enterprises (DXPE) is back on investors' radar after its share price moved higher, accompanied by a recent wave of upward earnings estimate revisions and consistently strong buy ratings from all covering analysts. See our latest analysis for DXP Enterprises. The recent uptick in earnings expectations appears to be feeding into strong momentum, with the share price at $143.34, a 90 day share price return of 36.85% and a 1 year total shareholder return of 95.15% highlighting sustained...

In early April 2026, Celldex Therapeutics completed a follow-on public equity offering of 10,345,000 common shares at US$29.00 each, raising about US$300.01 million to support barzolvolimab launch preparation, pipeline development and general corporate needs. This financing closely followed detailed Phase 2 data showing barzolvolimab’s potential to meaningfully improve quality of life in difficult-to-treat chronic urticaria, underscoring Celldex’s focus on translating clinical momentum into...

Recently, Cheniere Energy Partners highlighted that its long-term LNG capacity is largely contracted and that it has expanded supply agreements with counterparties in Thailand and Taiwan, supporting more predictable future volumes. An interesting angle is how these extended contracts, combined with management’s planned capacity expansions, could make the partnership’s cash flows more stable and less sensitive to short-term price swings. With the company’s shares posting modest gains over the...

Duke Energy (DUK) is back in focus after securing approval for a new natural gas plant in South Carolina, closing the sale of its Tennessee gas business, and reporting earnings that topped expectations. See our latest analysis for Duke Energy. The recent approval for new natural gas capacity in South Carolina and the completed sale of the Tennessee gas business arrive while Duke Energy’s 90 day share price return of 13.19% and 1 year total shareholder return of 15.11% suggest momentum has...

Aveanna’s latest earnings move and analyst reaction Aveanna Healthcare Holdings (AVAH) is back on investors’ radar after its fourth quarter update, where management reported 20.2% annual revenue growth and a 74.8% increase in Adjusted EBITDA, followed by Barclays revisiting its view on the stock. See our latest analysis for Aveanna Healthcare Holdings. At a latest share price of $6.38, Aveanna’s short term share price performance has been weak, with a 30 day share price return of an 11.8%...